KPC Pharmaceuticals Inc - Asset Resilience Ratio
KPC Pharmaceuticals Inc (600422) has an Asset Resilience Ratio of 16.37% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check KPC Pharmaceuticals Inc strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2004–2024)
This chart shows how KPC Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. See KPC Pharmaceuticals Inc (600422) balance sheet quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down KPC Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see KPC Pharmaceuticals Inc (600422) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥1.97 Billion | 16.37% |
| Total Liquid Assets | CN¥1.97 Billion | 16.37% |
Asset Resilience Insights
- Good Liquidity Position: KPC Pharmaceuticals Inc maintains a healthy 16.37% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
KPC Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare KPC Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867 |
Drug Manufacturers - Specialty & Generic | 0.76% |
|
Eris Lifesciences Limited
NSE:ERIS |
Drug Manufacturers - Specialty & Generic | 0.58% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Lotus Pharmaceutical Co Ltd
TW:1795 |
Drug Manufacturers - Specialty & Generic | 0.49% |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535 |
Drug Manufacturers - Specialty & Generic | 11.69% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 18.70% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Sun Pharma Advanced Research Company Limited
NSE:SPARC |
Drug Manufacturers - Specialty & Generic | 0.64% |
Annual Asset Resilience Ratio for KPC Pharmaceuticals Inc (2004–2024)
The table below shows the annual Asset Resilience Ratio data for KPC Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 3.74% | CN¥471.28 Million ≈ $68.96 Million |
CN¥12.61 Billion ≈ $1.85 Billion |
-2.58pp |
| 2023-12-31 | 6.31% | CN¥603.80 Million ≈ $88.35 Million |
CN¥9.57 Billion ≈ $1.40 Billion |
+2.93pp |
| 2022-12-31 | 3.39% | CN¥319.40 Million ≈ $46.74 Million |
CN¥9.43 Billion ≈ $1.38 Billion |
+1.58pp |
| 2021-12-31 | 1.80% | CN¥160.50 Million ≈ $23.49 Million |
CN¥8.89 Billion ≈ $1.30 Billion |
-2.32pp |
| 2020-12-31 | 4.12% | CN¥334.76 Million ≈ $48.99 Million |
CN¥8.12 Billion ≈ $1.19 Billion |
+1.28pp |
| 2019-12-31 | 2.84% | CN¥210.90 Million ≈ $30.86 Million |
CN¥7.43 Billion ≈ $1.09 Billion |
+1.30pp |
| 2018-12-31 | 1.54% | CN¥106.00 Million ≈ $15.51 Million |
CN¥6.89 Billion ≈ $1.01 Billion |
-8.95pp |
| 2017-12-31 | 10.49% | CN¥665.00 Million ≈ $97.31 Million |
CN¥6.34 Billion ≈ $927.47 Million |
-1.06pp |
| 2016-12-31 | 11.55% | CN¥624.00 Million ≈ $91.31 Million |
CN¥5.40 Billion ≈ $790.52 Million |
-3.22pp |
| 2015-12-31 | 14.77% | CN¥730.80 Million ≈ $106.94 Million |
CN¥4.95 Billion ≈ $724.09 Million |
+11.13pp |
| 2014-12-31 | 3.64% | CN¥110.00 Million ≈ $16.10 Million |
CN¥3.02 Billion ≈ $442.52 Million |
+3.59pp |
| 2004-12-31 | 0.04% | CN¥500.00K ≈ $73.17K |
CN¥1.17 Billion ≈ $171.49 Million |
-- |
About KPC Pharmaceuticals Inc
KPC Pharmaceuticals,Inc., a pharmaceutical company, engages in the research and development, production, marketing, and commercial wholesale of botanical drugs and natural drugs in the People's Republic of China and internationally. It offers artemisia annua series, panax notoginseng, gastrodia, artemether, specialty herbal, fine Chinese, and classic prescription for bones and joint, antibiotics,… Read more